Abstract
Several novel compounds recently appeared as promising leads to develop effective drugs against the basic defect in Cystic fibrosis (CF) and the first rationale therapies for CF relying on the understanding of the basic defect started to hit the clinical setting. Most of these efforts are focused on correcting the F508del mutation (occurring in ∼90% of CF patients) which causes misfolding of the CF transmembrane conductance regulator (CFTR) protein, the intracellular retention of such abnormal conformation by the endoplasmic reticulum quality control and premature degradation, thus precluding CFTR from reaching the cell membrane where it normally functions as a cAMP-stimulated Cl- channel. Here, several rationale therapeutic strategies are briefly reviewed, namely, mutation-specific (or “CFTR-repairing”) approaches (with a particular focus on the cellular defect associated with F508del-CFTR), manipulation of other ionic (non-CFTR) conductances and gene therapy. Still more innovative strategies, such as manipulation of the proteostasis network, displacement of molecular chaperones, targeting mutant CFTR by in silico small-molecule screens and systems biology approaches are also discussed.
Keywords: Basic defect, CFTR modulator, corrector, F508del, drug discovery, cystic fibrosis, pseudomonas aeruginosa, gene mutations, ionic conductances, chaperones
Current Drug Targets
Title: Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Volume: 12 Issue: 5
Author(s): Margarida D. Amaral
Affiliation:
Keywords: Basic defect, CFTR modulator, corrector, F508del, drug discovery, cystic fibrosis, pseudomonas aeruginosa, gene mutations, ionic conductances, chaperones
Abstract: Several novel compounds recently appeared as promising leads to develop effective drugs against the basic defect in Cystic fibrosis (CF) and the first rationale therapies for CF relying on the understanding of the basic defect started to hit the clinical setting. Most of these efforts are focused on correcting the F508del mutation (occurring in ∼90% of CF patients) which causes misfolding of the CF transmembrane conductance regulator (CFTR) protein, the intracellular retention of such abnormal conformation by the endoplasmic reticulum quality control and premature degradation, thus precluding CFTR from reaching the cell membrane where it normally functions as a cAMP-stimulated Cl- channel. Here, several rationale therapeutic strategies are briefly reviewed, namely, mutation-specific (or “CFTR-repairing”) approaches (with a particular focus on the cellular defect associated with F508del-CFTR), manipulation of other ionic (non-CFTR) conductances and gene therapy. Still more innovative strategies, such as manipulation of the proteostasis network, displacement of molecular chaperones, targeting mutant CFTR by in silico small-molecule screens and systems biology approaches are also discussed.
Export Options
About this article
Cite this article as:
D. Amaral Margarida, Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies, Current Drug Targets 2011; 12 (5) . https://dx.doi.org/10.2174/138945011795378586
DOI https://dx.doi.org/10.2174/138945011795378586 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amniotic Fluid Embolism: Review
Current Pharmaceutical Biotechnology Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design Effects of <i>Nigella Sativa</i> (Black seeds) Supplementation on Plasma Lipid Profile in Human Subjects - A Review
Current Nutraceuticals Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
Current Diabetes Reviews Late Life Depression: A Diagnostic and Pharmacological Review
Current Psychopharmacology Interest of α2-Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives
Current Topics in Medicinal Chemistry Therapeutic Macromolecular Iron Chelators
Current Medicinal Chemistry Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Life or Death? A Physiogenomic Approach to Understand Individual Variation in Responses to Hemorrhagic Shock
Current Genomics Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Structural and Pharmacological Features of Phospholipases A2 from Snake Venoms
Protein & Peptide Letters Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety A Proposal----The Renal Kallikrein-Kinin System as a Compensating System for Salt Accumulation after Excess Salt Intake
Current Hypertension Reviews A Walk in Nature: Sesquiterpene Lactones as Multi-Target Agents Involved in Inflammatory Pathways
Current Medicinal Chemistry